ChiCTR2300077475 版本V1.0 版本创建时间2023/11/09 16:34:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300077475 

最近更新日期:

Date of Last Refreshed on:

2023-11-09 16:34:36 

注册时间:

Date of Registration:

2023-11-09 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

腕部血压检测仪的安全性和有效性验证临床试验方案

Public title:

Safety and efficacy validation clinical trial protocol for wrist blood pressure monitors

注册题目简写:

English Acronym:

研究课题的正式科学名称:

腕部血压检测仪的安全性和有效性验证临床试验方案

Scientific title:

Safety and efficacy validation clinical trial protocol for wrist blood pressure monitors

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙文平 

研究负责人:

匡泽民 

Applicant:

Sun Wenping 

Study leader:

Kuang Zemin 

申请注册联系人电话:

Applicant telephone:

+86 199 2014 6974

研究负责人电话:

Study leader's telephone:

+86 185 1386 1179

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2439019230@qq.com

研究负责人电子邮件:

Study leader's E-mail:

kzmkk@foxmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市通州区新华南路82号

研究负责人通讯地址:

北京市通州区新华南路82号

Applicant address:

No.82, Xinhuanan Road, Tongzhou District, Beijing

Study leader's address:

No.82, Xinhuanan Road, Tongzhou District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京潞河医院

Applicant's institution:

Beijing Luhe Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京潞河医院

Affiliation of the Leader:

Beijing Luhe Hospital, Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-LHYW-035-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京潞河医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Beijing Luhe Hospital affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-06 00:00:00

伦理委员会联系人:

李海燕

Contact Name of the ethic committee:

Li Haiyan

伦理委员会联系地址:

北京市通州区新华南路82号

Contact Address of the ethic committee:

No.82, Xinhuanan Road, Tongzhou District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6056 9362

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京潞河医院

Primary sponsor:

Beijing Luhe Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市通州区新华南路82号

Primary sponsor's address:

No.82, Xinhuanan Road, Tongzhou District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

心永(天津)科技有限公司

具体地址:

天津市宝氓区京津中关村科技城西环北路1号协同发展中心1号楼 1004-1 室

Institution
hospital:

Xinyong (Tianjin) Technology Co., LTD

Address:

Building 1, Collaborative Development Center, No. 1 Xihuan North Road, Jingjin Zhongguancun Science and Technology City, Baomong District, Tianjin Room 1004-1

经费或物资来源:

申办方

Source(s) of funding:

Sponsor

Target disease:

Hypertension

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

对腕部血压检测仪投入市场前临床使用的安全性和有效性进行评价。  

Objectives of Study:

To evaluate the safety and effectiveness of the wrist blood pressure detector before being put into the market.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入本临床验证的受试者必须符合以下所有的标准方可入组: 1) 年龄18-75周岁,性别不限; 2) 收缩压范围为70-200mmHg,舒张压范围为50-130mmHg; 3) 愿意提供书面知情同意书的受试者。

Inclusion criteria

Participants included in this clinical trial must meet all of the following criteria to be enrolled: 1) Age 18-75 years old, gender is not limited; 2) Systolic blood pressure range is 70-200mmHg, diastolic blood pressure range is 50-130mmHg; 3) Subjects willing to provide written informed consent.

排除标准:

参与本临床试验的受试者若符合以下任一标准,则不可入组: 1) 不具有完全民事行为能力的人; 2) 既往患有严重心律失常(如室性二联律,室性三联率,心房颤动 等)的受试者; 3) 心脏起搏器植入术后的受试者; 4) 严重血管炎、严重血管硬化、严重皮肤角化症病史受试者; 5) 既往患有外周动脉疾病的受试者; 6) 测量部位肢体有伤口者; 7) 过去一个月内参加过临床试验或正在参加其他临床试验者。

Exclusion criteria:

Participants in this clinical trial will not be enrolled if they meet any of the following criteria: 1) Persons who do not have full capacity for civil conduct; 2) Subjects with prior severe arrhythmias (e.g., ventricular bisection, ventricular triple rate, atrial fibrillation, etc.); 3) Subjects after pacemaker implantation; 4) Subjects with a history of severe vasculitis, severe angiosclerosis, and severe cutaneous keratosis; 5) Subjects with prior peripheral artery disease; 6) The body of the measurement site has wounds; 7) Participants who have participated in clinical trials or are participating in other clinical trials within the past month.

研究实施时间:

Study execute time:

From 2023-07-06 00:00:00 To 2024-07-05 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-26 00:00:00 To 2024-07-05 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

水银血压计柯氏音双人听诊法

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Kirschner's sound double auscultation with mercury sphygmomanometer

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

腕部血压检测仪,收缩压/舒张压

Index test:

The wrist blood pressure detector, systolic/diastolic blood pressure

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

1) 年龄18-75周岁,性别不限; 2) 收缩压范围为70-200mmHg,舒张压范围为50-130mmHg; 3) 愿意提供书面知情同意书的受试者。

例数:

Sample size:

150

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

1) Age 18-75 years old, gender is not limited; 2) Systolic blood pressure range is 70-200mmHg, diastolic blood pressure range is 50-130mmHg; 3) Subjects willing to provide written informed consent.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

首都医科大学附属北京潞河医院 

单位级别:

三级 

Institution
hospital:

Beijing Luhe Hospital, Capital Medical University

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

收缩压/舒张压

指标类型:

主要指标

Outcome:

Systolic/diastolic blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

便捷度、舒适度

指标类型:

次要指标

Outcome:

Convenience and comfort

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

准确性

指标类型:

主要指标

Outcome:

Accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一致性

指标类型:

主要指标

Outcome:

Consistency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性

指标类型:

附加指标

Outcome:

Safety

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台ResMan (http://www.medresman.org.cn/login.aspx)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical trial public management platform ResMan (http://www.medresman.org.cn/login.aspx)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-11-09 16:34:36